174 related articles for article (PubMed ID: 14677621)
21. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
Anttila L; Neunteufel W; Petraglia F; Marr J; Kunz M
Clin Drug Investig; 2011; 31(8):519-525. PubMed ID: 21721590
[TBL] [Abstract][Full Text] [Related]
22. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund M; Røde A; Westergaard J
Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
[TBL] [Abstract][Full Text] [Related]
23. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
24. A multicenter clinical evaluation of a new monophasic combination: Minulet (gestodene and ethinyl estradiol).
de Andrade RP
Int J Fertil; 1989 Sep; 34 Suppl():22-30. PubMed ID: 2576253
[TBL] [Abstract][Full Text] [Related]
25. [Clinical study of two monophase oral contraceptives with desogestrel].
Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A
Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
Kroll R; Ackerman R; Feldman R; Howard B; Weiss H; Hsieh J; Ricciotti N
Contraception; 2016 Mar; 93(3):249-56. PubMed ID: 26499407
[TBL] [Abstract][Full Text] [Related]
27. Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene.
Renier M; Buytaert P
Contraception; 1991 May; 43(5):413-21. PubMed ID: 1914456
[TBL] [Abstract][Full Text] [Related]
28. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel.
Rekers H
Acta Obstet Gynecol Scand; 1988; 67(2):171-4. PubMed ID: 2972160
[TBL] [Abstract][Full Text] [Related]
29. Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive.
Ferguson H; Vree ML; Wilpshaar J; Eskes TK
Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):35-45. PubMed ID: 10836661
[TBL] [Abstract][Full Text] [Related]
30. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
Barbosa IC; Filho CI; Faggion D; Baracat EC
Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
[TBL] [Abstract][Full Text] [Related]
31. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
[TBL] [Abstract][Full Text] [Related]
32. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Dieben TO; op ten Berg MT; Coelingh Bennink HJ
Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
[TBL] [Abstract][Full Text] [Related]
33. [Clinical study of a low-dose contraceptive--Femodene].
Rachev E; Damianov L; Dukovski A; Katsarova M
Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
[TBL] [Abstract][Full Text] [Related]
34. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
35. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol. Latin American Oral Contraceptive Study Group.
Contraception; 1994 Sep; 50(3):201-14. PubMed ID: 7805371
[TBL] [Abstract][Full Text] [Related]
36. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
37. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
Norris LA; Bonnar J
Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
[TBL] [Abstract][Full Text] [Related]
38. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
Merz M; Kroll R; Lynen R; Bangerter K
Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
[TBL] [Abstract][Full Text] [Related]
39. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
40. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
Bilotta P; Favilli S
Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
